

8. **Amin MB, Menon S, Moch H.** Tumours of the penis and scrotum. in: WHO Classification of Tumours Editorial Board. Urinary and Male Genital Tumours. 5th ed. IARC 2022; 372–379.
9. **Michalová K, Beniač P, Kacerovská D.** Tumor lesions of penis and scrotum according to WHO classification 2022. *Cesk Patol.* 2022; 67(4): 192–197.
10. **Cubilla AL.** The role of pathologic prognostic factors in squamous cell carcinoma of the penis. *World J Urol.* 2009; 27: 169–177.
11. **Horenblas S, van Tinteren H.** Squamous cell carcinoma of the penis. IV. Prognostic factors of survival: analysis of tumor, nodes and metastasis classification system. *J Urol.* 1994; 151: 1239–1243.
12. **Srinivas V, Morse MJ, Herr HW, et al.** Penile cancer: relation of extent of nodal metastasis to survival. *J Urol.* 1987; 137: 880–881.
13. **Clark PE, Spiess PE, Agarwal N, et al.** National Comprehensive Cancer Network. Penile cancer: Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2013; 11(5): 594–615.
14. **Cubilla AL, Velazquez EF, Amin MB, et al.** The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expert-driven recommendations. *Histopathology.* 2018; 72: 893–904.
15. **Hrudka J, Prouzová Z, Kendall Bártů M, et al.** Immune cell infiltration, tumour budding, and the p53 expression pattern are important predictors in penile squamous cell carcinoma: a retrospective study of 152 cases. *Pathology.* 2023; 55(5): 637–649.
16. **Wen S, Ren W, Xue B, et al.** Prognostic factors in patients with penile cancer after surgical management. *World J Urol.* 2018; 36(3): 435–440.
17. **Naushad N, Deb AA, Agag AA, et al.** Prognostic Markers and Trials in Penile Cancer. *Urol Res Pract.* 2023; 49(3): 138–146.
18. **Guimarães GC, Cunha IW, Soares FA, et al.** Penile squamous cell carcinoma clinicopathological features, nodal metastasis and outcome in 333 cases. *J Urol.* 2009; 182(2): 528–534.
19. **Tang Y, Hu X, Wu K, Li X.** Immune landscape and immunotherapy for penile cancer. *Front Immunol* 2022; 13: 1055235.
20. **Wang Y, Wang K, Chen Y, et al.** Mutational landscape of penile squamous cell carcinoma in a Chinese population. *Int J Cancer.* 2019; 145(5): 1280–1289.
21. **Jacob JM, Ferry EK, Gay LM, et al.** Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. *J Urol.* 2019; 201(3): 541–548.
22. **Zhou QH, Deng CZ, Li ZS, et al.** Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines. *Cell Death Dis.* 2018; 9(6): 684.
23. **Olesen TB, Sand FL, Rasmussen CL, et al.** Prevalence of human papillomavirus DNA and p16INK4a in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. *Lancet Oncol.* 2019; 20(1): 145–158.
24. **May M, Burger M, Otto W, et al.** Ki-67, mini-chromosome maintenance 2 protein (MCM2) and geminin have no independent prognostic relevance for cancer-specific survival in surgically treated squamous cell carcinoma of the penis. *BJU Int.* 2013; 112(4): E383–390.
25. **Senapati R, Senapati NN, Dwibedi B.** Molecular mechanisms of HPV mediated neoplastic progression. *Infect Agent Cancer.* 2016; 11: 59.
26. **Manfredi JJ.** Mdm² and MdmX: Partners in p53 Destruction. *Cancer Res.* 2021; 81(7): 1633–1634.
27. **Buonerba C, Pagliuca M, Vitrone FM, et al.** Immunotherapy for penile cancer. *Future Sci OA.* 2017; 3(3): FSO195.